Dopamine News and Research

Latest Dopamine News and Research

McMaster researchers to use tiny worms for Parkinson's project

McMaster researchers from three disciplines are deploying thousands of tiny worms and a homegrown invention to test drugs in a collaborative bid to defeat Parkinson's Disease.

27 Jun 2011

ACS to honor Brookhaven Lab's senior chemist for brain research

Joanna Fowler, a senior chemist and director of radiotracer chemistry, instrumentation, and biological imaging at the U.S. Department of Energy's Brookhaven National Laboratory, is one of 23 women from around the world who has been chosen to receive a Distinguished Women in Chemistry/Chemical Engineering Award, sponsored by the American Chemical Society (ACS).

27 Jun 2011

Cocaine contaminated with livestock de-worming drug causes painful purpura

If the obvious reasons for avoiding recreational drug use aren't off-putting enough, physicians have yet another detrimental consequence to add to the list - crusty, purplish areas of dead skin that are extremely painful and can open the door to nasty infections.

24 Jun 2011

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.

24 Jun 2011

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

22 Jun 2011

Prior GID diagnosis impacts health outcomes of patients with Parkinson's

A new study investigating the incidence and impact of gastrointestinal disorders (GID) among patients with Parkinson's disease (PD) found that patients who received both a PD diagnosis and a prior GID diagnosis appeared to have worse health outcomes compared to patients who received a diagnosis for PD with no prior GID diagnosis.

16 Jun 2011

Music and drama therapy improve physical, emotional components of Parkinson's

Twice a month a jam session takes place on the third floor of Northwestern Memorial's Prentice Women's Hospital. A diverse group of men and women, ranging in age and ethnicity, gather in a circle with instruments in hand and sing together. This is no ordinary jam band; all its members have Parkinson's disease.

16 Jun 2011

Study investigates effects of dopamine replacement therapy on cognition in patients with Parkinson's

Dopamine replacement therapy, which is used to manage motor symptoms associated with Parkinson's disease, can, at times, adversely affect cognition.

15 Jun 2011

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

New findings from a multi-center, randomized, placebo-controlled clinical study of Deplin 15mg added to commonly prescribed antidepressants known as selective serotonin reuptake inhibitors showed that all patients who achieved remission at 30 days using Deplin 15mg adjuvant therapy, and who chose to enter a 12 month maintenance phase, maintained their remission after a year of treatment.

14 Jun 2011

Platelet-derived growth factor-BB restores function in rats with Parkinson's disease

Few treatments for Parkinson's disease (PD) restore function for extended periods. In a new study published today in the inaugural issue of the Journal of Parkinson's Disease, an international group of researchers report that platelet-derived growth factor-BB (PDGF-BB) restored function in rodents and shows promise as a clinical candidate drug for treatment of PD.

10 Jun 2011

Scripps Research receives $2.2M NIH grant to develop novel therapeutics for substance abuse

The Scripps Research Institute has been awarded a $2.2 million grant from the National Institutes of Health (NIH) to develop novel therapeutics for the treatment of addiction to multiple substances in a national effort with the University of Kansas.

10 Jun 2011

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in "off" time and an increase in "on" time without troublesome dyskinesias.

9 Jun 2011

Lund researchers create nerve cells from human skin

A research breakthrough has proven that it is possible to reprogram mature cells from human skin directly into brain cells, without passing through the stem cell stage. The unexpectedly simple technique involves activating three genes in the skin cells; genes which are already known to be active in the formation of brain cells at the foetal stage.

9 Jun 2011

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Neurologix, Inc. announced today several new results from the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) as part of a comprehensive presentation of study findings to the National Institutes of Health (NIH) Recombinant DNA Advisory Committee.

9 Jun 2011

Exposure to pesticides near any workplace increases risk of Parkinson's disease

In April 2009, researchers at UCLA announced they had discovered a link between Parkinson's disease and two chemicals commonly sprayed on crops to fight pests.

27 May 2011

Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress

Neurologix, Inc. announced the presentation today of efficacy results through one year of follow-up in patients treated as part of the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease.

27 May 2011

Scientists discover protein involved in nerve cell motor-cargo mechanism

With every bodily movement-from the blink of an eye to running a marathon-nerve cells transmit signals to muscle cells. To do that, nerve cells rely on tiny molecular motors to transport chemical messengers that excite muscles cells into action. It's a complex process, which scientists are still trying to understand. A new study by Syracuse University researchers has uncovered an important piece of the puzzle.

26 May 2011

Taking prenatal vitamins early during pregnancy can reduce risk of having children with autism

Women who reported not taking a daily prenatal vitamin immediately before and during the first month of pregnancy were nearly twice as likely to have a child with an autism spectrum disorder as women who did take the supplements - and the associated risk rose to seven times as great when combined with a high-risk genetic make-up, a study by researchers at the UC Davis MIND Institute has found.

26 May 2011

New data from ProSavin Phase I/II trial in Parkinson's presented at ASGCT annual meeting

Oxford BioMedica, a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin for the treatment of Parkinson's disease were presented at the American Society of Gene & Cell Therapy 14th Annual Meeting held in Seattle, USA by Professor Stephane Palfi, Principal Investigator at the Henri Mondor Hospital in Paris, on Saturday 21 May 2011.

23 May 2011

H. pylori infection could play a role in Parkinson's disease development

The stomach bacteria responsible for ulcers could also play a role in the development of Parkinson's disease according to research presented today at the 111th General Meeting of the American Society for Microbiology.

23 May 2011

Dopamine News and Research

Latest Dopamine News and Research

McMaster researchers to use tiny worms for Parkinson's project

ACS to honor Brookhaven Lab's senior chemist for brain research

Cocaine contaminated with livestock de-worming drug causes painful purpura

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Prior GID diagnosis impacts health outcomes of patients with Parkinson's

Music and drama therapy improve physical, emotional components of Parkinson's

Study investigates effects of dopamine replacement therapy on cognition in patients with Parkinson's

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

Platelet-derived growth factor-BB restores function in rats with Parkinson's disease

Scripps Research receives $2.2M NIH grant to develop novel therapeutics for substance abuse

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Lund researchers create nerve cells from human skin

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Exposure to pesticides near any workplace increases risk of Parkinson's disease

Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress

Scientists discover protein involved in nerve cell motor-cargo mechanism

Taking prenatal vitamins early during pregnancy can reduce risk of having children with autism

New data from ProSavin Phase I/II trial in Parkinson's presented at ASGCT annual meeting

H. pylori infection could play a role in Parkinson's disease development

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Dopamine News and Research

Latest Dopamine News and Research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in